Patent Protection Strategies: Maximising product Revenues

As new drug developments continue to necessitate increasingly high investments, successfully protecting revenue sustainability from the threat of low cost substitutes is reliant upon fully harnessing the efficacies of the patent system. In a market environment where competition from generics companies is becoming increasingly aggressive and the patenting of therapeutics is continually subject to impending legislative change, understanding how to effectively reassess, develop and exploit patent protection strategies is essential in facilitating enhanced market exclusivity and revenue returns over the lifecycles of new drugs. Patent Protection Strategies: Maximising product revenues is a new report published by Business Insights, examining the need for optimising and sustaining the patent protection of novel products. The report explores the best methods of exploiting legislation to maximise revenue generation and protecting the considerable investments associated with innovations. It will also examine the both the offensive and defensive tactics that can develop product lifecycle strategies, through the refinery of organisational patent protection in tandem to encumbering the market entry of generic substitutes. Use this report to understand how to successfully develop and apply patent protection strategies, exploit legislation effectively and secure the lifecyles of your innovations to maximise revenue returns...

Some key findings from this report...

• ANDA reviews are most effectively delayed by pursuing litigation for patent infringement.
• A recently established US Supreme Court ruling will extensively influence future patenting strategies, having been formed in the April 2007 US Supreme Court ruling on patentability involving KSR International Co -v- Teleflex Inc.
• Contingency plans can effectively counter failed or defective patent strategies, as shown in the Claritin and Prozac case studies.
• Successful patent protection strategies can vastly enhance the sustainability of product franchise revenues, significantly exceeding the lifetimes of basic patents. Prominent examples include AstraZeneca’s Losec and Nexium, and Amgen’s epoetin alfa.
• Holistic investigation of a firm’s ’Freedom to Operate’ is necessary prior to resource commital in product development or commercialization.

Top five reasons to order your copy today

1. Strengthen product protection by tailoring patent options to the individual specifications of your products more effectively.
2. Create a multi-strategy approach to defend your products and their revenues, as detailed within this report.
3. Enhance the efficacy of your patenting policy and opportunity management with explicit insights into the impending legislative
   changes concerning biosimilars and pediatric exclusivity, in addition to fallout analysis from the April 2007 Supreme Court ruling.
4. Integrate your patent protection and product lifecycle strategies with greater fluency, and reap the long term revenue benefits that improved synchronicity will afford.
5. Improve your current patenting practises by benchmarking case histories, and augment your organisation’s approach to achieve effective and successful strategy application.

Key issues examined in this report...

• Recouping drug development costs. The acute importance of sustainable market exclusivity for new drugs, through the use of patents and other legislative methods, in relation to recovering development costs and optimising revenue returns.
• US Supreme Court ruling. The scope of product patentability and patent protection strategies in general are widely expected to experience drastic changes as a result of the April 2007 ruling.
• Growing market prevalence of authorised generics. An industrywide debate has been evoked over the increasing use of authorized generics, based upon concerns over validity and consumer benefit.
• Biosimilar legislation. In June 2007, American Congress established a legal framework concerning the market admission of biosimilar products.
• Implications of declining NCE’s. Diminishing NCE’s highlight the importance of maximising patent protection for new drug entrants.

Your questions answered...

• How can the nominal 20 year period of patent protection be most effectively extended?
• What frameworks can be applied to formulate a holistic market strategy incorporating patent and product lifecycle considerations?
• How can the market entry of generic substitutes be delayed?
• Do significant differences exist between the patenting methods practised across the major markets?
• How may legislative changes impact upon future patent strategies and what areas of new legislisation are currently under discussion?
• What are the most effective patenting techniques and how can they be applied to maximise the sustainability of product revenues?